HC Wainwright Comments on Xeris Biopharma FY2026 Earnings

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) – Equities research analysts at HC Wainwright reduced their FY2026 earnings per share estimates for shares of Xeris Biopharma in a report issued on Friday, August 7th. HC Wainwright analyst B. Folkes now forecasts that the company will post earnings of $0.04 per share for the year, down from their previous estimate of $0.07. The consensus estimate for Xeris Biopharma’s current full-year earnings is $0.03 per share. HC Wainwright also issued estimates for Xeris Biopharma’s FY2028 earnings at $0.33 EPS, FY2029 earnings at $0.65 EPS and FY2030 earnings at $0.92 EPS.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 158.10% and a negative net margin of 5.12%.The business had revenue of $92.10 million for the quarter, compared to the consensus estimate of $90.12 million.

Other equities research analysts have also issued reports about the stock. Weiss Ratings upgraded shares of Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Wall Street Zen lowered shares of Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a research note on Saturday. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

Xeris Biopharma Stock Up 0.8%

Xeris Biopharma stock opened at $7.99 on Tuesday. The stock has a market capitalization of $1.38 billion, a PE ratio of -72.64 and a beta of 0.66. Xeris Biopharma has a twelve month low of $5.25 and a twelve month high of $10.08. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The company has a 50 day moving average of $7.72 and a 200-day moving average of $6.80.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of XERS. Royal Bank of Canada grew its stake in Xeris Biopharma by 1,411.2% in the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock valued at $1,170,000 after purchasing an additional 198,984 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Xeris Biopharma by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares in the last quarter. Millennium Management LLC raised its stake in shares of Xeris Biopharma by 19.0% during the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP acquired a new stake in shares of Xeris Biopharma in the 1st quarter valued at approximately $170,000. 42.75% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 16,667 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $6.06, for a total transaction of $101,002.02. Following the completion of the transaction, the insider directly owned 1,176,506 shares in the company, valued at $7,129,626.36. This represents a 1.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin Mcculloch sold 90,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total value of $722,700.00. Following the completion of the transaction, the insider owned 1,691,126 shares of the company’s stock, valued at $13,579,741.78. The trade was a 5.05% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 266,499 shares of company stock valued at $1,996,417 in the last three months. 4.35% of the stock is currently owned by insiders.

Xeris Biopharma Company Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.